- Home
- MGNX vs MMLP Comparison
MGNX vs MMLP Comparison
Compare MGNX & MMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MMLP
- Stock Information
- Founded
- MGNX 2000
- MMLP 2002
- Country
- MGNX United States
- MMLP United States
- Employees
- MGNX N/A
- MMLP N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MMLP Oil Refining/Marketing
- Sector
- MGNX Health Care
- MMLP Energy
- Exchange
- MGNX Nasdaq
- MMLP Nasdaq
- Market Cap
- MGNX 114.2M
- MMLP 111.3M
- IPO Year
- MGNX 2013
- MMLP 2002
- Fundamental
- Price
- MGNX $1.66
- MMLP $3.00
- Analyst Decision
- MGNX Hold
- MMLP
- Analyst Count
- MGNX 9
- MMLP 0
- Target Price
- MGNX $5.33
- MMLP N/A
- AVG Volume (30 Days)
- MGNX 770.0K
- MMLP 14.2K
- Earning Date
- MGNX 08-12-2025
- MMLP 07-16-2025
- Dividend Yield
- MGNX N/A
- MMLP 0.69%
- EPS Growth
- MGNX N/A
- MMLP N/A
- EPS
- MGNX N/A
- MMLP N/A
- Revenue
- MGNX $154,050,000.00
- MMLP $715,480,000.00
- Revenue This Year
- MGNX N/A
- MMLP $4.19
- Revenue Next Year
- MGNX N/A
- MMLP N/A
- P/E Ratio
- MGNX N/A
- MMLP N/A
- Revenue Growth
- MGNX 255.31
- MMLP N/A
- 52 Week Low
- MGNX $0.99
- MMLP $2.56
- 52 Week High
- MGNX $5.10
- MMLP $4.02
- Technical
- Relative Strength Index (RSI)
- MGNX 51.94
- MMLP 54.89
- Support Level
- MGNX $1.47
- MMLP $2.76
- Resistance Level
- MGNX $1.64
- MMLP $3.03
- Average True Range (ATR)
- MGNX 0.12
- MMLP 0.14
- MACD
- MGNX -0.00
- MMLP 0.01
- Stochastic Oscillator
- MGNX 26.83
- MMLP 91.89
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.